Gregory Renza
Stock Analyst at RBC Capital
(3.10)
# 1,546
Out of 4,555 analysts
161
Total ratings
39.87%
Success rate
1.76%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Initiates: Outperform | $35 | $26.36 | +32.78% | 1 | Sep 6, 2024 | |
| VRDN Viridian Therapeutics | Reiterates: Outperform | $35 | $14.19 | +146.65% | 7 | Aug 28, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $29 → $27 | $15.61 | +72.97% | 3 | Aug 16, 2024 | |
| VRCA Verrica Pharmaceuticals | Maintains: Outperform | $14 → $13 | $1.91 | +580.63% | 5 | Aug 15, 2024 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $6 → $4 | $0.24 | +1,544.74% | 7 | Aug 15, 2024 | |
| CRMD CorMedix | Reiterates: Outperform | $9 | $5.60 | +60.71% | 4 | Aug 15, 2024 | |
| ATYR aTyr Pharma | Reiterates: Outperform | $16 | $1.89 | +746.56% | 1 | Aug 14, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $70 → $68 | $19.30 | +252.33% | 2 | Aug 14, 2024 | |
| SPRB Spruce Biosciences | Reiterates: Sector Perform | $2 | $0.46 | +334.97% | 10 | Aug 13, 2024 | |
| PCRX Pacira BioSciences | Downgrades: Sector Perform | $37 → $14 | $13.23 | +5.82% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.51 | +417.93% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $11 → $8 | $6.41 | +24.80% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $36.45 | +67.35% | 10 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $25.51 | +5.84% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $26 | $15.77 | +64.87% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.75 | +190.91% | 11 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $332 → $362 | $325.92 | +11.07% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $19.89 | +55.86% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $2.97 | +68.35% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $55 | $43.93 | +25.20% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $174 | $106.46 | +63.44% | 8 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $23.44 | +15.19% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $8.63 | +62.22% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $18 | $0.35 | +5,060.55% | 7 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $8.15 | +2,108.59% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $3.30 | +2,324.24% | 4 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | n/a | $1.08 | - | 1 | Dec 11, 2019 |
Bicycle Therapeutics
Sep 6, 2024
Initiates: Outperform
Price Target: $35
Current: $26.36
Upside: +32.78%
Viridian Therapeutics
Aug 28, 2024
Reiterates: Outperform
Price Target: $35
Current: $14.19
Upside: +146.65%
Perspective Therapeutics
Aug 16, 2024
Maintains: Outperform
Price Target: $29 → $27
Current: $15.61
Upside: +72.97%
Verrica Pharmaceuticals
Aug 15, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.91
Upside: +580.63%
Viracta Therapeutics
Aug 15, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.24
Upside: +1,544.74%
CorMedix
Aug 15, 2024
Reiterates: Outperform
Price Target: $9
Current: $5.60
Upside: +60.71%
aTyr Pharma
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $1.89
Upside: +746.56%
Jasper Therapeutics
Aug 14, 2024
Maintains: Outperform
Price Target: $70 → $68
Current: $19.30
Upside: +252.33%
Spruce Biosciences
Aug 13, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $0.46
Upside: +334.97%
Pacira BioSciences
Aug 12, 2024
Downgrades: Sector Perform
Price Target: $37 → $14
Current: $13.23
Upside: +5.82%
Aug 9, 2024
Maintains: Outperform
Price Target: $16 → $13
Current: $2.51
Upside: +417.93%
Aug 9, 2024
Maintains: Sector Perform
Price Target: $11 → $8
Current: $6.41
Upside: +24.80%
Aug 7, 2024
Reiterates: Outperform
Price Target: $61
Current: $36.45
Upside: +67.35%
Aug 7, 2024
Reiterates: Outperform
Price Target: $27
Current: $25.51
Upside: +5.84%
Aug 7, 2024
Maintains: Outperform
Price Target: $29 → $26
Current: $15.77
Upside: +64.87%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.75
Upside: +190.91%
Aug 7, 2024
Maintains: Outperform
Price Target: $332 → $362
Current: $325.92
Upside: +11.07%
Aug 6, 2024
Reiterates: Outperform
Price Target: $31
Current: $19.89
Upside: +55.86%
Aug 6, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.97
Upside: +68.35%
Aug 2, 2024
Maintains: Outperform
Price Target: $53 → $55
Current: $43.93
Upside: +25.20%
Aug 1, 2024
Maintains: Outperform
Price Target: $175 → $174
Current: $106.46
Upside: +63.44%
Jul 12, 2024
Maintains: Outperform
Price Target: $26 → $27
Current: $23.44
Upside: +15.19%
Mar 13, 2024
Initiates: Outperform
Price Target: $14
Current: $8.63
Upside: +62.22%
Nov 10, 2023
Maintains: Outperform
Price Target: $23 → $18
Current: $0.35
Upside: +5,060.55%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $8.15
Upside: +2,108.59%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $3.30
Upside: +2,324.24%
Dec 11, 2019
Maintains: Outperform
Price Target: n/a
Current: $1.08
Upside: -